subscribeSubscribe
Syros To Host Webcast On MDS, Tamibarotene Opportunity In RARA Overexpression

Syros To Host Webcast On MDS, Tamibarotene Opportunity In RARA Overexpression
BUSINESSWIRE
13 Jun 2024
Share Share
Rege Nephro: Phase 2 Tamibarotene Trial In ADPKD Patient Enrollment

Rege Nephro: Phase 2 Tamibarotene Trial In ADPKD Patient Enrollment
PR NEWSWIRE
28 May 2024
Share Share
Syros Highlights 2024 Milestones to Deliver on the Value of Tamibarotene

Syros Highlights 2024 Milestones to Deliver on the Value of Tamibarotene
BUSINESSWIRE
08 Jan 2024
Share Share
Syros’ stock up after sharing early, mid-stage AML data

Syros’ stock up after sharing early, mid-stage AML data
Gabrielle Masson FIERCE BIOTECH
07 Dec 2023
Share Share
Syros Announces Initial Data from Phase 2 Trial Evaluating Tamibarotene

Syros Announces Initial Data from Phase 2 Trial Evaluating Tamibarotene
BUSINESSWIRE
06 Dec 2023
Share Share
Syros Receives Fast Track Designation from the FDA for Tamibarotene

Syros Receives Fast Track Designation from the FDA for Tamibarotene
BUSINESSWIRE
26 Jan 2023
Share Share
Syros Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene

Syros Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene
BUSINESSWIRE
12 Dec 2022
Share Share
Syros Reports Second Quarter 2022 Financial Results

Syros Reports Second Quarter 2022 Financial Results
BUSINESSWIRE
09 Aug 2022
Share Share
Syros Receives Positive Opinion on Orphan Drug Designation from the EMA

Syros Receives Positive Opinion on Orphan Drug Designation from the EMA
BUSINESSWIRE
03 Aug 2022
Share Share
FDA orphan drug designation for treatment of rare blood cancer

FDA orphan drug designation for treatment of rare blood cancer
PHARMAFILE
03 Feb 2022
Share Share